Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Finerenone for Kidney and Vascular Protection in CKD
2025-522503-18-00Phase 4Authorised
- Sponsor
- Central Denmark Region
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide and finerenone in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Central Denmark Region. Planned start Sep 2025; status: authorised.
02
Drugs
semaglutidefinerenone
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-522503-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522503-18-00.